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Basement membrane biosynthesis as a target for developing inhibitors
of angiogenesis with anti-tumor properties. Basement membrane (BM)
exerts profound influence on endothelial cell (EC) behavior. In addition
BM is a structural element of blood vessels; in fact at some point of
their formation blood vessels are bare EC tubes lined with the BM
produced by these EC. We thought, therefore, that a quantitative
relationship must exist between the rate of BM synthesis and angiogen-
esis, and that interfering with BM synthesis must have an effect on
angiogenesis. This was found experimentally in the chick chorioallan-
toic membrane (CAM) system. It was shown that the rate of BM
collagen biosynthesis can serve as a biochemical index of angiogenesis
and that inhibitors of BM synthesis prevent angiogenesis. GPA 1734
(8,9-dihydroxy-70-methyl-benzo(b)quinolizinium bromide), which in-
hibits proline and lysine hydroxylations in type IV collagen formation,
suppresses angiogenesis in the CAM. Similarly, D609 (tricyclodecan-9-
yl-xanthate), which inhibits BM synthesis by an as yet unknown
mechanism, also prevents angiogenesis. Structurally related analogs of
GPA 1734 and D609 that have no effect on BM biosynthesis are also
without effect on angiogenesis. The aforementioned inhibitors of angio-
genesis GPA 1734 and D609 have a dose-dependent inhibitory effect on
tumor growth in rats bearing Walker 256 carcinosarcoma, without any
obvious toxic effects. This effect is probably related to angiosuppres-
sion, since structurally related analogs that do not inhibit angiogenesis
are without antitumor properties. Also GPA 1734 and D609 have no
direct cytotoxic effects on Walker 256 cells in vitro. These results
suggest that a search for agents that are specific inhibitors of BM
synthesis may provide novel angiosuppressors with potential applica-
tion in tumor chemotherapy. There are many enzymatic steps in the
biosynthesis and assembly of BM that are possible targets for develop-
ing inhibitors of angiogenesis. Such inhibitors are not expected to have
serious side effects for short-term treatment, since both BM synthesis
and angiogenesis are extremely slow processes under physiological
conditions.
Basement membrane (BM) biosynthesis plays a pivotal role
in angiogenesis. In addition to providing the substrate for
attachment and anchorage of the proliferating EC, BM modu-
lates their growth and differentiation [1]. Individual components
of BM have different effects on EC growth and morphology in
vitro and there is a temporally ordered appearance of these
components during angiogenesis [2]. It is obvious, therefore,
that derangement of BM, which is synthesized by EC during
angiogenesis, is expected to have a profound effect on angio-
genesis. Furthermore, because at the early stages of neovascu-
larization blood capillaries are bare EC tubes lined by BM
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produced by these EC, a quantitative relationship is reasonable
to exist between the rates of BM synthesis and angiogenesis.
In this report we review some of our recent findings that BM
synthesis can serve as convenient biochemical index of angio-
genesis [3] and that inhibition of BM synthesis results in
angiosuppression [4]. These findings provide the basis of meth-
odology for developing angiogenesis inhibitors with antitumor
potential [5].'
Methods
GPA 1734 (8,9 dihydroxy-7-methylbenzo(b)quinolizinium
bromide) and GPA 1967 (9,10 dihydroxy-7-methylbenzo(b)qui-
nolizinium bromide) were prepared by Dr. J. Watthey of
CIBA-GEIGY Corporation (Summit, New Jersey, USA). D609
(tricyclodecan-9-yl-xanthate) and analogs were obtained from
Dr. Schatton, Merk & Co., Frankfurt, Germany. L-U'4C pro-
line was obtained New England Nuclear Corporation (Boston,
Massachusetts, USA). Collagenase was type VII from Clostrid-
ium histolyticum and was purchased from Sigma Chemical Co.
(St. Louis, Missouri, USA). Plastic discs used were square 22 X
22 mm plastic dispo coverslips (MG100) from Scientific Prod-
ucts (McGraw Park, Illinois, USA), which were cut into round
disks with a diameter of about 10 mm.
Fresh, fertilized eggs were obtained locally (Astir Co., Pa-
tras, Greece) and were kept at 10°C before incubation at 37°C.
The surface of the eggs and all instruments were disinfected
with 70% isopropyl alcohol.
The chick chorioallantoic membrane (CAM) assay of
angiogenesis
This assay was used as described previously [3, 4]. Biochem-
ical assays for collagenous proteins, total proteins were also
detailed in previous reports [3, 4].
Culture of Walker 256 carcinoma cells
Freshly dissected rat carcinoma specimens were minced in a
petri dish, and cells were dispersed after incubation with 0.25%
trypsin + EDTA 0.02% at 37°C for five minutes. Trypsinization
'Abbreviations are: BM, basement membrane; CAM, chick cho-
rioallantoic membrane; EC, endothelial cell; GPA 1734, 8,9-dihydroxy-
7-methyl-benzo(b) quinolizinium bromide; GPA 1967, 9, lO-dihydroxy-
7-methyl-benzo(b) quinolizinium bromide; D609, tricyclodecan-9-yl-
xanthate.
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Table 1. Identification of collagenous protein synthesized by CAM as
BM collagen type IV
Solubilized radioactivity
DPM % of total
'4C]-CAM proteinsa + C. 2870 245 9.8 0.8
collagenase (15, IU)
['4C]-CAM proteinsa + tumor 3450 95 11.1 0.3
type IV collagenase (8 sg
protein)
[14C1-CAM protein? + type 170 40 2.1 0.8
IV collagen (1 mg) +
tumor type IV collagenase
a Samples of CAM after incubation with [14C]-proline in vitro as
described in the Methods section were washed with TCA to remove
non-precipitable radioactivity, Samples (N = 12) from a suspension of
['4C1-CAM proteins were treated either with C. collagenase or with type
IV tumor collagenase in the presence and absence of excess type IV
"cold" collagen.
was stopped by washing cells with culture medium 199 (Flow
Laboratories, Irvine, UK) containing 10% fetal calf serum and
20 mst glutamine. Cells were then washed three times with
Tris-phosphate buffer, pH 7.4 and collected after centrifugation
at 800 x g. These cells (0.5 x 106 cells/mI) were then cultured
in the 199 medium (containing 10% fetal calf serum and 20 mss
glutamine) adjusted to pH 6.8.
Incubations were performed in water-jacketed CO2 incubator
at 37°C under constant supply of a mixture of 95% air and 5%
CO2. Viability was determined by trypan blue and cells were
counted under microscope using a hemocytometer.
Animal studies
Wistar male rats weighing about 150 to 200 g were used for
intra-abdominal transplantation of Walker 256 carcinoma as
described previously [51.
Statistical methods
Results were analyzed by the Student's t-test or paired t-test
as described by Schefler [61 and Lutz [71.
Results
Rate of BM biosynthesis as an index of angiogenesis
When collagenous protein biosynthesis by CAM was mea-
sured in vitro and in vivo at different days of chick embryo
development, it was found that it was maximum at the stage of
maximum angiogenesis, that is, at day 10. On day 15 when
angiogenesis had reached a plateau, the rate of collagenous
protein synthesis was less than 10% of the maximum observed
on day 10 [3]. The collagenous protein synthesized by the CAM
appears to be mainly type IV collagen because it can be
degraded by a specific collagenase type IV purified from Walker
256 carcinosarcoma [8]. As shown in Table 1, CAM proteins
labeled with U-14C-proline were solubilized to the same extent
by Clostridia! collagenase and a type of IV collagenase. The
degradation by type IV collagenase was greatly reduced when
excess cold type IV collagen was added. In addition, the
biosynthesis of the collagenous proteins were inhibited by GPA
1734, an inhibitor of type IV collagen formation described
previously [9]. Total protein synthesis or thymidine incorpora-
Table 2. Effect of D609 on total protein and BM collagen
biosynthesis in the CAM system in vitro
Total
incorporation Collagenous
from [U- protein
'4C]-proline synthesis
DPM/mg protein x
Treatment N jo SE
Control 8 162.8 11.8 18.7 1.6
D609 (1 pgIm1) 8 154.7 9.5 14.2 1.3
D609 (5 pg/m!) 8 122.6 10.0 7.7 1.1
D609 (10 p.g/ml) 8 105.6 6.9 6.3 0.7
D609 (25 g/m!) 8 62.2 6.5 3.4 0.3
D609 (50 tsg/m1) 8 28.1 2.0 1.8 0.1
Ethyl-xanthate (25 g/m1) 7 164.5 7.2 19.3 1.9
Propyl-xanthate (25 jsg/ml) 4 189.9 17.9 20.6 1.4
Experimental details are described in the Methods.
tion into DNA of CAM were largely unaffected by GPA 1734
[3].
In the CAM system agents that promote angiogenesis, such
as hyaluronic acid digests [31, leukotrienes, etc., caused a
marked increase in the rate of collagenous protein biosynthesis.
On the contrary, known inhibitors of angiogenesis, such as
heparin + cortisone [101, cause a depression in the rate of
collagenous proteins synthesized by the CAM [11]. Using this
methodology, we initiated a search for inhibitors of BM biosyn-
thesis and studied their effect on angiogenesis.
Inhibitors of BM synthesis and their effect on angiogenesis in
the CAM system
GPA 1734 is a previously studied inhibitor of proline and
lysine hydroxylation of BM collagen synthesis by the rat
parietal yolk sac [9]. In this system it was shown that inhibition
of the postnbosomal hydroxylation reactions of proline and
lysine renders the unhydroxylated product of BM type IV
collagen susceptible to proteolytic degradation by endogenous
proteases and unsuitable for deposition to the pre-existing BM
of the yolk sac. A closely related analog, GPA 1967 (9,10-
dihydroxy-7-methyl benzo(b)quinolizinium bromide) had no
similar effects on BM synthesis and deposition [9].
We tested the effects of these compounds or the CAM system
both in vitro and in vivo. As is the case for the yolk sac, GPA
1734 inhibited collagenous protein synthesis in the CAM while
GPA 1967 was without effect at comparable concentrations [4].
At the minute concentrations that GPA 1734 inhibited BM
collagen biosynthesis it prevented angiogenesis without any
apparent effect on the pre-existing blood vessels. On the
contrary, in the presence of the inactive analog GPA 1967,
angiogenesis proceded unaffected.
Encouraged by these results we initiated a search for specific
inhibitors of BM synthesis using the aforementioned methodol-
ogy of CAM in vitro and in vivo. One of the inhibitors that was
identified was D609 (tricyclodecan-9-yl-xanthate). This com-
pound has an inhibitory effect on collagenous protein synthesis
by CAM in vitro, which was far more pronounced than its
inhibitory effect on total protein synthesis (Table 2). Ethyl and
propyl-xanthates are analogs of D609 without effect on BM
synthesis in vitro. When 30 to 50 g D609 was placed on the
CAM under the in vivo conditions described in the methods
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Table 3. Effect of GPA 1734 on Walker 256 carcinoma growth
Tumor Animals
Treatment Body weight weight
bearing
implants
Implants
per
mg/kg/day N g % animal
Control 30 170 5 14.7 1.0 100.0 over 100
GPA 1734 12.5 6 162 5 (NS) 10.7 1.oa 33.3 17 I
GPA 1734 25.0 10 175 7 (NS) 8.9 2.0" 20.0 14 2
GPA 1734 50.0 18 148 4 (NS) 4.9 1.0" 16.7 8 2
GPA 1734 100.0 6 161 1 (NS) 4.0 0.5" 0.0 0
Data are mean values SE. Results for N number of animals, were
compared statistically with the control group and are significant at P <
0.01 () and at P <ooo1(b), or are non-significant (NS).
there was a marked inhibition of collagenous protein synthesis
and angiogenesis [51.
Effect of angiogenesis inhibitors on tumor cells in culture and
on tumor growth
Both GPA 1734 and D609 were tested for their antitumor
effects on rats bearing Walker 256 carcinosarcoma.
Animals were treated daily i.p. with GPA 1734 at the doses
indicated in Table 3. In all control animals the intraperitoneally
transplanted tumor increased considerably in size within nine
days of implantation. In addition, to the main mass multiple
implants were observed macroscopically which were seeded
along the spleen, hilus and the whole length of the mesenteric
attachment to the intestinal track. Tumor mass was weighed
after dissection and was 14.7 1.1 g for 30 control rats.
Histologically the tumors had the characteristics of the parent
Walker 256 carcinoma.
In the animals treated with GPA 1734 the tumor mass formed
after nine days showed a dose-dependent decrease (Table 3). At
the highest dose employed, 100 mg/kg/day, the tumor mass was
reduced to 4.0 0.5 in the treated group. Tumors were
localized at the site of implantation and appeared in spherical
masses 5 to 8 mm in diameter. Both the number of implants per
animal and the number of animals bearing implants were
reduced in a dose-dependent fashion, and the tumor was
confined around the site of the initial tumor transplantation.
Preliminary toxicity studies with GPA 1734 administered
intraperitoneally indicated an LD50 for rats of 200 mg/kg. With
100 mg/kg the rats were either ataxic or prostrate, and respira-
tion was slow and shallow (hypopnea). With 50 mg/kg/day
administered for seven days, there were no aberrant behavioral
signs clearly related to the intraperitoneal dose of the sub-
stance. Occasionally, rats appeared to struggle on day 2 and
there was a suggestion of the compound being irritating, but
struggling by the animals ceased thereafter despite continuation
of treatment. At necropsy, the peritoneal membranes, abdom-
inal cavity and major organs appeared normal. There was a
slight but insignificant decrease in body weight.
Treatment of rats with D609 also resulted in a dose-depen-
dent decrease of tumor mass. As shown in Table 4, doses of 25
mg/kg/day i.p. caused 67% inhibition in the growth of tumor
mass after nine days. The inactive analogs ethyl and propyl
xanthate were without effect. The animals gained weight nor-
mally and there was no evidence for toxic effects. This com-
pound was also tested p.o. at doses 40 mg/kg/day by gastric
Table 4. Effect of D609 and analogs on tumor growth in the Walker
256 rat carcinosarcoma model
Treatment
Number
of rats
Body
Initial
weight
Final
Tumor mass
g
Inhibition
%
Control 11 171 7 179 8 6.2 0.4 —
D609 5 190 7 202 5 1.6 0.3 67
Ethylxanthate 11 185 8 198 9 6.7 0.6 0
Propylxanthate 11 156 9 174 8 6.3 0.6 0
Except for controls, rats were treated with 25 mg/kg/day i.p. with the
compounds tested. Results are expressed as means SE.
Table 5. Effect of D609 on Walker 256 rat carcinoma cells in culture
Treatment No. of cells after 48 hr
Control 3.3 x 10/2.5 ml
Control + D609 50 p.g/ml 0.7 x 106/2.5 ml
Control + D609 25 pg/ml 2.2 x 106/2.5 ml
Control + D609 10 p.g/ml 2.2 x 106/2.5 ml
Control + D609 5 ,ug/ml 2.5 x 106/2.5 ml
The cells were obtained from rat Walker 256 carcinoma and incu-
bated as described in the Methods. At zero time the number of cells
present in each flask were 1.2 x 106/2.5 ml.
intubation. In the group of 20 rats treated with D609 p.o. there
was a marked delay in death rate. Twenty-five percent survived
after 30 days. In three of the five survived there was no tumor
to be measured while in the other two rats the tumor size
averaged 1 to 2 g [5].
The antitumor effect of D609 on Walker 256 carcinosarcoma
is unlikely to be related to direct cytotoxic effects on tumor
cells. As shown in Table 5 the presence of D609 at concentra-
tions of less than 25 g/ml in the culture medium for 48 hours
caused only a small decrease in viable cell numbers as com-
pared to controls. The number of cells in the controls increased
from 1.2 x 106 cells/2.5 ml to 3.3 X 106 cells/2.5 ml within 48
hours of incubation, In the presence of D609 at 5 to 25 g/ml the
corresponding number of viable cells were 2.2 to 2.5 x 106
cell/2.5 ml. The higher concentration 50 ig/ml caused some cell
death and prevented cell growth.
Discussion
Abnormal angiogenesis is involved in a variety of disease
states such as arthritis, psoriasis, diabetic retinopathy, chronic
inflammation, hemangiomas, retrolental fibroplasia, etc. In ad-
dition, a hypothesis has been advanced by Folkman that tumors
are angiogenesis dependent and therefore preventing angiogen-
esis may be a new approach to cancer therapy [121. Further-
more, it has been recognized that angiogenesis is a marker that
precedes tumorigenicity [13] and thus might serve as a general
marker of neoplastic transformation.
These observations generated the need to understand the
cellular and molecular mechanisms which control angiogenesis
and to develop substances that inhibit angiogenesis, because
they may have exciting therapeutic potential.
In spite of the impressive progress in the field, it is generally
recognized that a major difficulty in the study of angiogenesis is
the lack of suitable in vivo and in vitro assays. Several in vivo
methods have been employed such as the CAM, the rabbit
cornea pocket assay, etc. However, all these in vivo assays are
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morphological and the evaluation of angiogenesis is cumber-
some, expensive, and even in expert hands provides semiquan-
titative results. On the other hand, the in vitro assays based on
endothelial cell cultures with components of extracellular ma-
tnx [14] may not appropriately represent the complex cascade
of events leading to neovascularization in vivo.
Our approach to use the biosynthesis of BM collagen type IV
in vivo provides a reasonable biochemical index of angiogene-
sis. As it has already been pointed out, under normal physio-
logical conditions (in non-embryonic situations) both BM syn-
thesis and angiogenesis are extremely slow processes. By
contrast, when activated in pathophysiological conditions the
vascular endothelium can express instantaneously all the infor-
mation necessary to program the construction of new capillary
networks. The turnover of BM is very slow in normal tissues,
and biosynthesis of BM proceeds at a measurable rate only in
embryonic tissues such as lens, glomeruli, yolk sac, etc. [15].
Therefore, in the absence of angiogenesis one would not expect
high background rate of BM biosynthesis.
We have also shown that inhibitors of BM synthesis prevent
angiogenesis [3, 4]. It is not known at present by what mecha-
nism inhibition of type IV collagen synthesis, and prolyl hy-
droxylation by GPA 1734 or the inhibition of other step(s) of
BM synthesis by D609, leads to the prevention of new blood
vessel formation without an effect on pre-existing vessels. It is
likely that by interfering with the synthesis of one component of
BM, the synthesis of other components becomes impaired so
that the complex structure of BM, which is an essential element
of all blood vessels, cannot be completed. Alternatively, pre-
venting the proliferating EC to form type IV collagen by GPA
1734 may deprive them of the extracellular matrix component,
which is essential for organization into tube-like structures [14].
In any case, BM synthesis seems to be a good target for the
development of specific inhibitors of angiogenesis with thera-
peutic potential. Many enzymatic steps in the biosynthesis of
the various components of BM or the assembly of these
macromolecules into BM are potential targets for developing
angiogenesis inhibitors. Because of the extremely slow turn-
over rate of BM, these inhibitors are unlikely to have serious
side effects during short-term treatment. This was shown to be
the case with GPA 1734 and D609 in rats. These compounds, as
do other angiogenesis inhibitors, such as protamine or heparin
+ cortisone [10], have anti-tumor effects. Such agents may
open a new therapeutic approach to solid tumor therapy, which
can be used alone or in combination with existing therapies.
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